@article{b4ba4d3873ce414ea50a3833ddc20039,
title = "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial",
abstract = "Background the anti-cd52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.",
author = "Coles, {Alasdair J.} and Twyman, {Cary L.} and Arnold, {Douglas L.} and Cohen, {Jeffrey A.} and Christian Confavreux and Fox, {Edward J.} and Hans-Peter Hartung and Eva Havrdova and Selmaj, {Krzysztof W.} and Weiner, {Howard L.} and Tamara Miller and Elizabeth Fisher and Rupert Sandbrink and Lake, {Stephen L.} and Margolin, {David H.} and Pedro Oyuela and Panzara, {Michael A.} and {CARE-MS | Investigators} and Raymond Hupperts and Compston, {D. Alastair S.}",
year = "2012",
month = nov,
day = "24",
doi = "10.1016/S0140-6736(12)61768-1",
language = "English",
volume = "380",
pages = "1829--1839",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Science",
number = "9856",
}